Yayınları
x
KÝTAP
Editörlük:
1-Yasko JM. Kemoterapiye baðlý belirtilerin denetimi ve bakýmý. Ed. E Topuz, H ONAT, Istanbul, 1993
2- ONAT H, Mandel NM. Kanser hastasýna yaklaþým. Istanbul, 2002.
3- ONAT, H, Demir Ç, Saðlýk ve kanserde doðru beslenme, 2007
4-ONAT H, Onkoloji bölümü, Ýç Hastalýklarý Genel Ed Erol Ç, 2008
5. Kanser hastasýna yaklaþým. Yenilenmiþ 2.baskýsý, Istanbul 2011
Bölüm yazarlýðý:
1-Tangün Y, ONAT H. Kanser kemoterapisi. Teþhisten tedaviye.
Ed. Aleksanyan V, Istanbul, 1991, 1297- 1337.
2-ONAT H: Küçük hücreli akciðer kanseri kemoterapisi. Akciðer Kanseri. Ed. E Topuz, 1995, 103-111
3- ONAT H, Epitelyal over kanserinde kemoterapi. Over Kanseri. Ed. E. Topuz. 1996, 135-144.
4- ONAT H, Meme Kanseri risk faktörleri ve korunma. Meme Kanseri. Ed. E. Topuz 1997, 102-117.
5- ONAT H, Malign kemik tümörleri. Klinik Onkoloji. Ed. E.Topuz, A.Aydýner, AN Karadeniz, 2000, 242-244.
6- ONAT H. Kanser tanýsýndan tedaviye geçiþ süreci. Kanser hastasýna yaklaþým. Ed. H.ONAT, NM Mandel. 2002, 87-93
7- Argon A, ONAT H. Kanserde yorgunluk.Kanser hastasýna yaklaþým. Ed. H ONAT, NM Mandel, 2002, 255-259
8- ONAT H. Meme kanseri risk faktörleri ve korunma. In: Meme Kanser Ed E Topuz, A Aydýner, M Dinçer ,2003, 90-107
9- ONAT H. Ýleri evre ve metastatik mesane kanserlerinde sistemik kemoterapi, Uroonkoloji. Ed. H Özen, LTürkeri, 2007, 347-355
10- ONAT H. Kanser hastasýna yaklaþým. In: Ýç hastalýklarý Ed Erol Ç, 2008, 235 – 240
11- Baþaran G, Baþaran M, ONAT H. Prostat kanseri In: Ýç hastalýklarý Ed Erol Ç, 2008, 397 – 408
12- ONAT H. Meme kanseri. In: Ýç hastalýklarý Ed Erol Ç, 2008, 427 – 440
13- ONAT H. Kanser tanýsýndan tedaviye geçiþ süreci. Kanser hastasýna yaklaþým. Ed. H.ONAT, NM Mandel. 2011, 131-136
14- Yýldýrým Y , ONAT H.Gebelik ve Kanser. Kanser hastasýna yaklaþým. Ed. H.ONAT, NM Mandel. 2011, 331-336
15- Demir Ç, ONAT H. Kanserli hastada beslenme Kanser hastasýna yaklaþým. Ed. H.ONAT, NM Mandel. 2011, 489-503
16- Argon A, ONAT H. Kanserde yorgunluk.Kanser hastasýna yaklaþým. Ed. H ONAT, NM Mandel, 2011, 513-517
YURTDIÞI MAKALE
1-ONAT H, Ýnceman Þ, Bilge N, Dinçol K, Töre G, Topuz E.
Effect of Tamoksifen on Antithrombin III activation in breast cancer.
Proc 15 th Interantional congress of chemotherapy 279-281, 1987.
2-Yasasever V, Bilge N, Töre G, ONAT H, Enginun M.
Menstural cycle values of tumor marker in healthy women and in patients with non- gynecological tumors.
Clin Exp Obst Gyn 17 (3-4): 121-129, 1990.
3- ONAT H, Yasasever V, Þengün Z, Dalay N.
Osteocalcin: A valuable bone metastasis marker.
Eur J Gynaec Oncol 12(5): 399-402, 1991.
4-Yasasever V, Þengün Z, Saydan N, ONAT H, Dalay N.
Serum values of CA 72.4 in patients with gastrointestinal system tumors comparison with CEA and Ca 19.9.
Eur J Gynaec Oncol 13(5): 403-408, 1992.
5- Yasasever V, Karaloðlu D, Yazýcý H, ONAT H, Dalay N.
Serum neu oncoprotein levels as a tumor marker in breast cancer.
J Tumor Marker Oncol 7(2): 33-42, 1992.
6-ONAT H, Altun M, Bilge N, Karadeniz A, Ertürk N, Aydýner A, Aykan F.
Neoadjuvant chemotherapy and radiotherapy in locally advanced undifferentiated nasopharyngeal carcinoma.
J Exp Clin Res 11(3): 203-206, 1992.
7- ONAT H, Ýnanç ES, Yasasever V, Dalay N.
Effects of cisplatin on erythropoietin and iron changes.
Eur J Can 29A(5): 777, 1993.
8- Aydýner A, ONAT H, Öztürk N, Aykan F, Ýnanç S, Topuz E, Dinçol K.
The efficacy of a five drug antiemetic combination on the consequent cisplatin and cyclophosphamide-doxorubicin containing chemotherapy regimen.
J Pain and Synptom Management 8(3): 126-131, 1993.
9- Ýnanç ES, ONAT H.
Brief weekly chemotherapy for elderly patients with intermediate grade anf high grade on Hodgkin Lymphoma.
J Nat Can Inst 85(13). 1088, 1993.
10- Aykan NF, Bilge N, ONAT H, Kýnay M, Topuz E, Dinçol K, Necatioðlu B, Uzal C.
Le role de prognostic des transfusions sanguýnes dans la maladie de Hodgkin .
Med Bull Istanbul 26: 38-42, 1993.
11-Aydýner A, Olgaç V, Darendeliler E, Öztürk N, Dinçol K, Erseven G, ONAT H.
Testicular germ cell tumor with gastric metastasis.
Acta Oncol 32(4): 459, 1993.
12- Ýnanç Es, Altun M, ONAT H, Erseven G.
Sweet’s syndrome and Hodgkin’s disease
Acta Oncol 33(5): 574-575, 1994.
13-ONAT H, Ýnanç S, Karaloðlu D, Ertürk N, Dalay N, Yasasever V.
Acute coagulation changes during cytotoxic chemotherapy.
J Exp Clin Cancer Res. 13(1): 89-92, 1994.
14-Baltalý E, Ýçli F, Molinas Mandel N, ONAT H, Aktan G, Ober A, Üskent N, Kýnay M, Berk Ö, Fýrat D.
Neoadjuvant weekly epirubicin chemotherapy of locally advanced breast cancer.
Proc International cancer congress, 1451-1453, 1994.
15- Dinçol D, Mandel N, Barýþta I, Aktan G, ONAT H, Sardaþ OS, Berk Ö, Çehrelli C, Fýrat D.
Weekly epirubicin in combination chemotherapyint the treatment of intermediate and high grade non- Hodgkin’s lymphoma.
Proc International cancer congress, 2633-2637, 1994.
16-Karaloðlu D, Yazýcý H, Alatlý C, Yaman F, Aslay I, ONAT H, Dalay N.
Detection og HPV 16 and HPV 18 infection in patients with cervical neoplasia.
Eur. J. Gynaec. Oncol. 17 (4) 296-298, 1995.
17- ONAT H.
Nasopharyngeal cancer.
Recenti progressi nel controllo farmacologico dei tumori 207- 212, 1996.
18- Fýrat D, Baltalý E, Ýçli F, ONAT H, Mandel N, Berk Ö, Ober A, Aktan G.
Phase II study of weekly doses of epiubicin in advanced breast cancer.
Turkish J Cancer 26(2): 62- 69, 1996.
19- Berk Ö, ONAT H, Kars A, Serdengeçti S, Günel N, Aykan F, Okkan S, Kýnay M, Üskent N, Aktan G, Fýrat D.
High dose epirubicin and ifosfamide alteranting with etoposide and cisplatin therapy with granulocyte macrophage colony stimulating factor in small cell lung cancer.
Turkish J Cancer 26(3): 119-126, 1996.
20- Kurul S, Ýnanç S, Darendeliler E, ONAT H, Çakmak M, Topuzlu C, Aslay I, Erseven G.
Reconstruction after resection of soft tissue sarcoma of the trunk.
Med. Bull. Ýstanbul, 29(2): 77- 83, 1996
21- ONAT H, Ýnanç ES, Saip P, Topuz E.
Prevention of chemotherapy induced emesis in patients with germ cell tumors
receiving multiple day cisplatin based chemotherapy.
Turkýsh J Cancer 26(4): 159-164, 1996.
22- Ýnanç SE, ONAT H, Oðuz H, Topuz E.
Autoimmune phenomena in patients receiving alpha interferon therapy.
Cancer Invest 14(6): 642-643, 1996.
23- Saip P, ONAT H, Ýnanç SE, Topuz E, Diþçi R.
The effect of donzetron and dowpenidon as antiemetics in breast cancer patients receiving cyclophosphamide, epirubicin and fluorouracil during three subsequent courtes.
Turkish J Cancer 27(1): 27-36, 1997.
24. Dinçol D, Molinas NM, Barýþta Ý, Aktan G, ONAT H, Sardaþ OS, Berk Ö, Çehreli C,
Fýrat D.
Combination chemotherapy involving weekly epirubicin in the treatment of intermediate and high grade non-Hodgkin’s lymphomas.
Turkish J Cancer 27(3): 91-97, 1997.
25. Saip P, Ýnanç SE, ONAT H.
Mesna/Ifosfamide, Mitoxamtrone and Etoposide combination chemotherapy in refractory and relapsing non-Hodgkin’s lymphoma.
J BUON 2:145-150, 1998.
26. Saip P, Yasasever V, Tenekeci N, Aydýner A, Ýnanç S, ONAT H, Diþci R, Topuz E.
Prediction of radiological response of bone metastases to therapy by biochemical marker
monitoring in patients with breast cancer.
J Tumor Marker Oncol 13(3):45-52, 1998.
